January 2022 Top Biopharma Deal: Beam – Pfizer In Vivo Base Editing and Delivery Programs for Rare Diseases

by | Feb 10, 2022

January 2022 Top Biopharma Deal Upfront

Beam research partnership with Pfizer with a license option for up to three therapies for rare genetic diseases

Announced: January 10, 2022

Total Deal Value: $1,350M

Upfront Cash: $300M

Upfront Equity: n/a

R&D Funding: n/a

Milestones: up to $1,050M (dev., reg., and sales)

Royalty: Undisclosed, per program.

Cost and Profit Split: 65%/35% (Pfizer/Beam) if co-dev and co-pro option is exercised

The Asset:

Beam’s proprietary in vivo base editing and LNP delivery technologies for the treatment of rare genetic diseases of the liver, muscle, and CNS

Deal Structure:

Option to License

Partnership Features:

Option to Co-Develop and Co-Promote with Shared Costs

The Details:

  • Beam signed a three year research partnership with Pfizer to co-develop in vivo base editing programs against three targets using its in vivo base editing and delivery technologies for the treatment of rare genetic diseases of the liver, muscle, and central nervous system with an exclusive, worldwide option to license each program.
  • Beam may opt-in to global co-development and co-promotion for one licensed program; exercisable at the end of Phase 1/2 by paying an option exercise fee.
  • Beam will receive $300M up front and is eligible to receive up to $1.05B in development, regulatory, and sales milestones, plus royalties per licensed program if not opted for co-development / co-promotion.
  • If Beam opts in to co-dev/co-pro, both companies will share cost and profits 65%/35% (Pfizer/Beam).

Last Month:

Congrats to Beam and Pfizer for landing DealForma’s January 2022 Top Biopharma Deal. Last month’s Deal of the Month was Foghorn – Loxo using Gene Traffic Control for new oncology treatments. Read about it here.

DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms. We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.

Want data for your analysis? Want us to do it? Subscribers get both.

Schedule your demo of the DealForma database to see how we help you get better reports done faster.


Deal Profiles


Funding Rounds


Company Profiles


Product Profiles


Clinical Trials


Business Developers

Specifically for Biotech, Pharma, Device, and Diagnostics

Get more done.

Stop cleaning data or getting lost in legacy databases. We built DealForma to help you be better and faster at business research. Schedule your customized demo to see how DealForma helps you impress your boss and sign-off early.

More Research by DealForma

Biotech and Pharma M&A in 2020

Biotech and Pharma M&A in 2020

Biotech and pharma M&A total deal values slumped in 2020, despite an active year in life sciences dealmaking, with no big standout biopharma deals until late in the second half of the year. We look at the extensive DealForma database to see how life sciences M&A activity shaped up in 2020 in more detail.

read more

You met on Zoom. Now it's Deal Time.

With thousands of company profiles and a decade of deals specifically in biopharma and medtech, you'll take the guesswork out of deal comps. Schedule your customized demo to see how DealForma helps you win that term sheet with better data.